BRISBANE, Calif., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the second quarter ended June 30, 2013.
Key financial highlights for the second quarter of 2013 were as follows:
- Revenue was $19.6 million, which remained flat compared to the second quarter in 2012.
- Gross margin improved to 57%, compared to 53% in the second quarter of 2012, due primarily to a favorable product mix shift and the realization of several cost reduction initiatives.
- Net loss was $0.6 million, or $0.04 per diluted share. Non-cash items including stock-based compensation, intangible, and depreciable items totaled $1.1 million for the quarter.
- Cash generated from operations was $1.9 million.
- Balance sheet remains strong with $89.6 million in cash and investments, an increase of over $8.2 million during the past year.
Kevin Connors, President and CEO of Cutera, stated, "The revenue growth experienced in many segments of our global markets, was offset by the negative impact of the devalued Japanese Yen versus the US Dollar and the softening of our Canadian business. The Japanese Yen devalued by approximately 24% against the US dollar from 80 at June 30, 2012, to 99 at June 30, 2013.
During the quarter, we made certain sales management and structural changes in our North American sales organization. We are currently in the midst of a sales force expansion in North America, which includes some sales specialists focused on increasing our market penetration into the core market with our high-performance vascular workstation − Excel-V. Our success with this product has been exceptional in certain regions and we see even broader opportunities if we provide additional structural focus. With these changes, coupled with other expansion initiatives, we believe we are well-positioned to improve our performance in this region."
Mr. Connors concluded that, "We anticipate a continued improvement in our gross margin levels as our volume improves, demonstrating the leverage in our business model. As such, with our controlled operating expenses, we believe we are continuing to improving profitability."
Our engineering team continues to deliver and has made solid progress towards new product development activities:
- We recently launched a new truSculpt applicator to treat smaller cosmetic areas. Given our flat applicator design, we believe that this product will allow physicians to treat smaller areas more effectively.
- Our program to introduce a high-performance laser system that will focus on a large market segment within the aesthetic light-based market is progressing as planned. We recently submitted our 510(k) application to the FDA for this device and look forward to its launch.
- Our dual wavelength picosecond program for the tattoo removal and pigmented lesion markets has commenced clinical trials for both indications and are now in the process of compiling the information for our 510(k) submission.
Our Board of Directors recently authorized the repurchase of up to $10.0 million of our stock, which is not subject to a 10b5-1 plan. This is in addition to our currently active $10.0 million stock repurchase program that is subject to a 10b5-1 plan, under which purchases would occur at pre-determined parameters.
The conference call to discuss these results is scheduled to begin at 2:00 p.m. PT (5:00 p.m. ET) on August 5, 2013. Participating in the call will be Kevin Connors, President and Chief Executive Officer, and Ron Santilli, Executive Vice President and Chief Financial Officer. The call will be broadcast live over the Internet hosted at the Investor Relations section of Cutera's website at www.cutera.com, and will be archived online within one hour of its completion through 8:59 p.m. PT (11:59 p.m. ET) on August 19, 2013. In addition, you may call 877-407-3982 to listen to the live broadcast.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning Cutera's ability to increase revenue, improve cash generation from operations, improve gross and net operating margins, develop and commercialize existing and new products and applications, experience market adoption for its products, realize benefits from additional investment, expand its sales force, plans for stock repurchases and statements regarding long-term prospects and opportunities in the laser and other energy-based equipment aesthetic market are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Potential risks and uncertainties that could affect Cutera's business and cause its financial results to differ materially from those contained in the forward-looking statements include those related to the Company's efforts to improve sales productivity, revenue growth and profitability improvement through the leverage of its operating expenses; the Company's ability to successfully develop and launch new products and applications and market them to both its installed base and new customers; the length of the sales cycle process; unforeseen events and circumstances relating to the Company's operations; government regulatory actions; and those other factors described in the section entitled, "Risk Factors" in its most recent Form 10-Q as filed with the Securities and Exchange Commission on August 5, 2013. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. Cutera's financial performance for the second quarter ended June 30, 2013, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30,||March 31,||June 30,|
|Cash and cash equivalents||$11,885||$17,272||$17,788|
|Accounts receivable, net||7,542||6,814||6,203|
|Deferred tax asset||39||39||52|
|Other current assets and prepaid expenses||1,429||1,511||1,443|
|Total current assets||109,154||107,548||101,002|
|Property and equipment, net||1,338||1,312||946|
|Deferred tax asset, net of current portion||504||518||463|
|Other long-term assets||348||362||539|
|Liabilities and Stockholders' Equity|
|Total current liabilities||17,091||16,014||17,866|
|Deferred revenue, net of current portion||2,844||2,538||1,400|
|Income tax liability||325||320||905|
|Other long-term liabilities||1,386||1,449||469|
|Additional paid-in capital||105,954||105,089||98,044|
|Accumulated other comprehensive income (loss)||(40)||83||(325)|
|Total stockholders' equity||93,255||93,150||87,675|
|Total liabilities and stockholders' equity||$114,901||$113,471||$108,315|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except per share data)|
|Three Months Ended|
|June 30,||March 31,||June 30,|
|Cost of revenue||8,442||7,417||9,274|
|Sales and marketing||7,170||6,456||7,112|
|Research and development||2,217||2,121||1,872|
|General and administrative||2,354||2,289||2,854|
|Total operating expenses||11,741||10,866||11,838|
|Loss from operations||(623)||(2,316)||(1,521)|
|Interest and other income, net||75||135||144|
|Loss before income taxes||(548)||(2,181)||(1,377)|
|Provision (benefit) for income taxes||90||(18)||89|
|Net loss per share:|
|Weighted-average number of shares used in per share calculations:|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Three Months Ended|
|June 30,||March 31,||June 30,|
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash provided by (used in) operating activities:|
|Depreciation and amortization||326||320||425|
|Changes in assets and liabilities:|
|Other current assets and prepaid expenses||182||60||59|
|Other long-term assets||14||35||(81)|
|Other long-term liabilities||(34)||259||(24)|
|Income tax liability||5||(92)||--|
|Net cash provided by (used in) operating activities||1,872||(543)||(851)|
|Cash flows from investing activities:|
|Acquisition of property and equipment||(178)||(525)||(34)|
|Proceeds from sales of marketable and long-term investments||4,475||500||7,066|
|Proceeds from maturities of marketable investments||5,150||11,050||8,700|
|Purchase of marketable investments||(16,770)||(20,473)||(10,094)|
|Net cash provided by (used in) investing activities||(7,323)||(9,448)||5,638|
|Cash flows from financing activities:|
|Proceeds from exercise of stock options and employee stock purchase plan||64||3,717||214|
|Net cash provided by financing activities||64||3,717||214|
|Net increase (decrease) in cash and cash equivalents||(5,387)||(6,274)||5,001|
|Cash and cash equivalents at beginning of period||17,272||23,546||12,787|
|Cash and cash equivalents at end of period||$11,885||$17,272||$17,788|
|CONSOLIDATED FINANCIAL HIGHLIGHTS|
|(in thousands, except percentage data)|
|Three Months Ended||% Change|
|Q2||Q1||Q2||Q2 '13 Vs.||Q2 '13 Vs|
|2013||2013||2012||Q1 '13||Q2 '12|
|Revenue By Geography:|
|International as a percentage of total revenue||61%||59%||60%|
|Revenue By Product Category:|
|Products and upgrades||$13,034||$9,197||$12,487||+42%||+4%|
|Titan and truSculpt hand piece refills||1,106||1,190||1,216||-7%||-9%|
|Dermal fillers and cosmeceuticals||913||1,136||1,453||-20%||-37%|
|Three Months Ended|
|Pre-tax Stock-Based Compensation Expense:|
|Cost of revenue||$166||$159||$168|
|Sales and marketing||198||199||159|
|Research and development||89||101||147|
|General and administrative||349||361||313|
CONTACT: Cutera, Inc. Ron Santilli Chief Financial Officer 415-657-5500 Investor Relations John Mills Integrated Corporate Relations, Inc. 310-954-1105 email@example.comSource:Cutera, Inc.